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USE OF PROBIOTIC BACTERIAL STRAINS 
AND CELL EXTRACTS TO INHIBIT 
ACIDOSIS AND LIVER ABSCESSES IN 
CATTLE 
INCORPORATION OF SEQUENCE LISTING 
[ 0001 ] A paper copy of the Sequence Listing and a com 
puter readable form of the Sequence Listing containing the 
file named “ 2016 - 079 ST25 . txt ” , which is 2 , 582 bytes in size 
( as measured in MICROSOFT WINDOWS® EXPLORER ) , 
are provided herein and are herein incorporated by refer 
ence . This Sequence Listing consists of SEQ ID NOs : 1 - 2 . 
bacteria , colonizes through the area of superficial necrosis 
produced due to the acidity of the rumen contents . Leuko 
toxin may facilitate resistance to phagocytosis . Bacterial 
emboli from the lesions invade the hepatic portal venous 
system and are transported to the liver , where they can 
establish infectious foci of necrobacillosis that eventually 
develop into abscesses . 
10006 ] While there are current therapies available for 
controlling liver abscesses , these therapies have met with 
little success . For example , while tylosin phosphate has been 
found to reduce the number of liver abscesses and increases 
feed efficiency and weight gain , it has little , if any , effect on 
prevalence of ruminal lesions . Further , with dairy cattle , 
percutaneous drainage and long - term therapy with procaine 
penicillin G can be attempted , but the prognosis is poor . 
Accordingly , the primary control is by managing ruminal 
acidosis through the method of feeding , adaptation using 
diet composition , diligent feed bunk management , and use 
of buffers in the diet . 
[ 0007 ] Based on the foregoing , there is a need in the art for 
alternative therapies for reducing acidosis and / or liver 
abscesses in livestocks , particularly , cattle . In some forms , it 
would be beneficial if the therapy could be added directly to 
feed as a feed additive , or as a direct fed microbial ( DFM ) 
product . In other forms , it would be beneficial if the therapy 
could be formulated for topical application . 
BACKGROUND OF THE DISCLOSURE 
[ 0002 ] The present disclosure relates generally to the use 
of bacterial strains useful as probiotics . In some forms , these 
bacterial strains synthesize and excrete antimicrobial com 
pounds and extracts that have beneficial effects . More par 
ticularly , the present disclosure is directed to the use of 
probiotic bacterial strains Aneurinibacillus migulanus and 
Aneurinibacillus aneurinilyticus and their extracts for inhib 
iting the growth of Streptococcus bovis , Fusobacterium 
necrophorum and Acranobacterium ( Actinomyces ) pyo 
genes . These bacterial strains and their extracts can be used 
in cattle to treat acidosis and / or liver abscesses , as well as 
inhibit foot rot , and other infections and conditions caused 
by Streptococcus bovi and / or Fusobacterium necrophorum 
and / or Acranobacterium ( Actinomyces ) pyogenes . 
10003 ) Liver abscesses are seen in all ages and breeds of 
cattle . They are most common in feedlot and dairy cattle fed 
rations that are high in fermentable starches that predispose 
the animal to acidosis and rumenitis . Cattle with acidosis 
and liver abscesses have reduced production efficiency . The 
affected livers are condemned at slaughter , and adhesions to 
surrounding organs or the diaphragm may necessitate car 
cass trimming . Liver abscesses can also lead to disease 
syndromes associated with posterior vena caval thrombosis . 
[ 0004 ] Fusobacterium necrophorum , a gram - negative , 
obligate anaerobic bacterium , and a component of normal 
rumen microflora , is the primary etiologic agent of liver 
abscesses . Infection in the liver usually originates from a 
necrobacillary rumenitis . Two biovars have been implicated . 
Biovar A ( F . necrophorum necrophorum ) , the more virulent , 
is the predominant biovar in the rumen microflora and is 
isolated , usually in pure culture , from most cases of liver 
abscessation . Biovar B ( F necrophorum funduliforme ) is 
commonly isolated from microabscesses in the rumen wall , 
but is less commonly isolated from liver abscesses , in which 
it is always found in mixed culture with biovar A or other 
bacterial species . Acranobacterium ( Actinomyces ) pyo 
genes , Streptococci , Staphylococci , and Bacteroides spp are 
most frequently recovered from mixed cultures . 
[ 0005 ] Rumenitis is usually the result of rapid intra 
ruminal fermentation of dietary carbohydrate with subse 
quent production of lactic acid and increased acidity of the 
ruminal fluid ( “ grain overload " ) . Rations with high levels of 
carbohydrate are the principal cause in both dairy and 
feedlot cattle , but the texture of the feed and method of 
feeding can be modifying factors . The incidence of rume 
nitis in feedlot cattle is significantly higher when the cattle 
are transferred directly from a roughage ration to a high 
starch ( high energy ) finishing ration , and when there is poor 
feed bunk management . F necrophorum , alone or with other 
BRIEF DESCRIPTION OF THE DISCLOSURE 
[ 0008 ] The present disclosure is generally related to the 
use of probiotic bacterial strains Aneurinibacillus migulanus 
and Aneurinibacillus aneurinilyticus and / or extracts thereof 
for inhibiting the growth of Streptococcus bovis , Fusobac 
terium necrophorum and Acranobacterium ( Actinomyces ) 
pyogenes . Growth of Streptococcus bovis , Fusobacterium 
necrophorum and Acranobacterium ( Actinomyces ) pyo 
genes has been linked to acidosis , which leads to liver 
abscesses in livestock , as well as foot rot , particularly in 
feedlot and dairy cattle . Accordingly , by inhibiting the 
growth , the present disclosure can provide treatment for 
these conditions and ailments . 
[ 0009 ] Accordingly , in one aspect , the present disclosure 
is directed to a method of inhibiting Streptococcus bovis in 
a subject in need thereof , the method comprising adminis 
tering to the subject an effective amount of a bacterial strain 
selected from the group consisting of Aneurinibacillus migu 
lanus , Aneurinibacillus aneurinilyticus or an extract thereof 
and combinations thereof . Preferably the inhibition is at 
least 5 % , more preferably at least 10 % , still more preferably 
at least 20 % , even more preferably at least 30 % , still more 
preferably at least 40 % , even more preferably at least 50 % , 
still more preferably at least 60 % , even more preferably at 
least 70 % , still more preferably at least 80 % , even more 
preferably at least 90 % , and most preferably between 95 % 
and 100 % . 
[ 0010 ] In another aspect , the present disclosure is directed 
to a method of inhibiting Fusobacterium necrophorum and 
Acranobacterium ( Actinomyces ) pyogenes in a subject in 
need thereof , the method comprising administering to the 
subject an effective amount of a bacterial strain selected 
from the group consisting of Aneurinibacillus migulanus , 
Aneurinibacillus aneurinilyticus or an extract thereof and 
combinations thereof . Preferably the inhibition is at least 
5 % , more preferably at least 10 % , still more preferably at 
least 20 % , even more preferably at least 30 % , still more 
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preferably at least 40 % , even more preferably at least 50 % , 
still more preferably at least 60 % , even more preferably at 
least 70 % , still more preferably at least 80 % , even more 
preferably at least 90 % , and most preferably between 95 % 
and 100 % . 
[ 0011 ] In yet another aspect , the present disclosure is 
directed to a method of reducing the incidence or severity of 
acidosis in a subject in need thereof , the method comprising 
administering to the subject an effective amount of a bac 
terial strain selected from the group consisting of Aneurini 
bacillus migulanus , Aneurinibacillus aneurinilyticus or an 
extract thereof and combinations thereof . Preferably the 
reduction is at least 5 % , more preferably at least 10 % , still 
more preferably at least 20 % , even more preferably at least 
30 % , still more preferably at least 40 % , even more prefer 
ably at least 50 % , still more preferably at least 60 % , even 
more preferably at least 70 % , still more preferably at least 
80 % , even more preferably at least 90 % , and most prefer 
ably between 95 % and 100 % . 
[ 0012 ] In yet another aspect , the present disclosure is 
directed to a method of reducing the incidence or severity of 
liver abscesses or foot rot in a subject in need thereof , the 
method comprising administering to the subject an effective 
amount of a bacterial strain selected from the group con 
sisting of Aneurinibacillus migulanus , Aneurinibacillus 
aneurinilyticus or an extract thereof and combinations 
thereof . In some forms , the reduction in the incidence of 
liver abscesses is in comparison to a similar sized animal or 
herd of animals and is based on the total number of liver 
abscesses or foot rot lesions or the percentage of animals 
with liver abscesses or foot rot . Preferably the reduction is 
at least 5 % , more preferably at least 10 % , still more pref 
erably at least 20 % , even more preferably at least 30 % , still 
more preferably at least 40 % , even more preferably at least 
50 % , still more preferably at least 60 % , even more prefer 
ably at least 70 % , still more preferably at least 80 % , even 
more preferably at least 90 % , and most preferably between 
95 % and 100 % . 
[ 0013 ] In another aspect , the present disclosure is directed 
to a method of treating foot rot in a subject in need thereof , 
the method comprising administering to the subject an 
effective amount of a bacterial strain selected from the group 
consisting of Aneurinibacillus migulanus , Aneurinibacillus 
aneurinilyticus or extract thereof and combinations thereof . 
[ 0014 ] In yet another aspect , the present disclosure is 
directed to a method of controlling liver abscesses and / or 
foot rot in an animal or herd of animals , the method 
comprising administering an effective amount of a bacterial 
strain selected from the group consisting of Aneurinibacillus 
migulanus , Aneurinibacillus aneurinilyticus or an extract 
thereof and any combination thereof to an animal or to the 
animals of the herd . In some forms , controlling liver 
abscesses and / or foot rot is in comparison to the animal or 
herd of animals and is based on the total number of liver 
abscesses or foot rot areas or the percentage of animals with 
liver abscesses or foot rot before and after receiving a 
composition comprising at least one of the bacterial strains . 
A further comparison can be made to a similar sized animal 
or herd of animals that has not received administration of a 
composition comprising at least one of the bacterial strains . 
In other forms , controlling is measured by comparing the 
severity of the liver abscesses or foot rot before and after 
receiving an administration of a composition comprising at 
least one of the bacterial strains . Preferably evidence of 
controlling is provided by having at least 5 % less progres 
sion in severity or in the number of liver abscesses or areas 
of foot rot or their severity , more preferably at least 10 % , 
still more preferably at least 20 % , even more preferably at 
least 30 % , still more preferably at least 40 % , even more 
preferably at least 50 % , still more preferably at least 60 % , 
even more preferably at least 70 % , still more preferably at 
least 80 % , even more preferably at least 90 % , and most 
preferably between 95 % and 100 % after receiving an admin 
istration of a composition comprising the bacterial strains . In 
some forms , this progression is measured by comparing the 
number of liver abscesses or areas of foot rot from before the 
administration of a composition comprising at least one of 
the bacterial strains to the number of liver abscesses or areas 
of foot rot after the administration of a composition com 
prising at least one of the bacterial strains . 
[ 0015 ] In another aspect , the present disclosure is directed 
to a method of treating foot rot in a subject in need thereof , 
the method comprising administering to the subject an 
effective amount of a bacterial strain selected from the group 
consisting of Aneurinibacillus migulanus , Aneurinibacillus 
aneurinilyticus or extract thereof and any combination 
thereof . In some forms , the administration comprises the 
step of applying an amount of at least one of the bacterial 
strains to the feet of a subject in need thereof . In some forms , 
the bacterial strains will be incorporated into a gel , cream , 
spray , or lotion . In other forms , the bacterial strains will a 
component in an aqueous medium that will be applied 
topically to an area affected by foot rot . Preferred routes of 
topical administration include spraying , submersion in a 
bath , and the like . 
[ 0016 ] In yet another aspect , the present disclosure is 
directed to a composition comprising an amount of at least 
one bacterial strain selected from the group consisting of 
Aneurinibacillus migulanus , Aneurinibacillus aneurinilyti 
cus or extract thereof and any combination thereof . In some 
forms of the composition , both bacterial strains are present . 
In some forms of the composition , the bacterial strains 
include live cultures combined with feed . In some forms of 
the composition , the bacterial strains are lyophilized . Such 
lyophilized forms can be reconstituted or administered in 
their lyophilized form . Such lyophilized forms can also be 
combined with feed . In some forms of the composition 
including live cultures or lyophilized bacterial strains , the 
bacterial strains are combined or mixed with a prebiotic . 
Such combinations can be added to feed . In some forms of 
the composition , the composition is formulated for oral 
administration . In some forms of the composition , the com 
position is formulated for topical formulation . 
[ 0017 ] In yet another aspect , the present disclosure is 
directed to a kit comprising the composition as described 
herein . In some forms , the kit includes a container for 
housing the components of the kit . In some forms , the kit 
includes instructions for use . 
[ 0018 ] In still another aspect , the present disclosure is 
directed to a foot bath comprising an amount of a bacterial 
strain selected from the group consisting of Aneurinibacillus 
migulanus , Aneurinibacillus aneurinilyticus or extract 
thereof and any combination thereof in an aqueous environ 
ment . Such a bath is configured for insertion of a foot or hoof 
therein such that the aqueous portion of the bath contacts 
portions of the hoof or foot susceptible to foot rot . 
US 2019 / 0269740 A1 Sep . 5 , 2019 
ul of crude cell extract , Cell extract 500 - induced with 
glucose in the presence of 500 ul of crude cell extract , and 
Live cells - induced with glucose in the presence of 10° live 
Aneurinibacillus anerinilyticus UNL P2C12 cells . In the live 
cells , a rapid initial pH drop is seen due to Aneurinibacillus 
anerinilyticus UNL P2C12 cells utilizing the glucose added 
to induce acidosis . However , protection is seen from the live 
cells 5 hours after induction . 
DETAILED DESCRIPTION 
BRIEF DESCRIPTION OF THE DRAWINGS 
[ 0019 ] The patent or application file contains at least one 
drawing executed in color . Copies of this patent or patent 
application publication with color drawing ( s ) will be pro 
vided by the Office upon request and payment of the 
necessary fee . 
[ 0020 ] The disclosure will be better understood , and fea 
tures , aspects and advantages other than those set forth 
above will become apparent when consideration is given to 
the following detailed description thereof . Such detailed 
description makes reference to the following drawings , 
wherein : 
[ 0021 ] FIG . 1 depicts the results from initial screening 
showing potential candidates that were used for further 
screening as described in the Example . The antimicrobial 
assay shown is against Streptococcus bovis ATCC 700410 
( JB1 ) . “ A ” denotes Aneurinibacillus migulanus and “ B ” 
denotes Aneurinibacillus anerinilyticus UNL P2C12 show 
ing inhibition of the growth of Streptococcus bovis . The 
species identification was performed on the candidate iso 
lates . 
[ 0022 ] FIGS . 21 & 2B depict results of the antimicrobial 
assay against Streptococcus bovis ATCC 700410 ( JB1 ) . FIG . 
2A depicts 50 ul of cell extract from 24 - hour old culture of 
Aneurinibacillus migulanus ( “ A ” ) and Aneurinibacillus 
anerinilyticus UNL P2C12 ( “ B ” ) showing inhibition of the 
growth of Streptococcus bovis . FIG . 2B depicts 50 ul of cell 
free media from 72 - hour old culture of Aneurinibacillus 
migulanus ( “ A ” ) and Aneurinibacillus anerinilyticus UNL 
P2C12 ( “ B ” ) showing inhibition of the growth of Strepto 
coccus bovis . 
[ 0023 ] FIGS . 3A & 3B depict results of the antimicrobial 
assay against Fusobacterium necrophorum ATCC 27852 . 
FIG . 3A depicts 50 ul of cell extract from 24 - hour old culture 
of Aneurinibacillus migulanus ( “ A ” ) and Aneurinibacillus 
anerinilyticus UNL P2C12 ( “ B ” ) showing inhibition of the 
growth of Fusobacterium necrophorum . FIG . 3B depicts 50 
ul of cell free media from 72 - hour old culture of Aneurini 
bacillus migulanus ( “ A ” ) and Aneurinibacillus anerinilyti 
cus UNL P2C12 ( “ B ” ) showing inhibition of the growth of 
Fusobacterium necrophorum . 
[ 0024 FIG . 4 depicts results of the antimicrobial assay 
control showing that cell growth inhibition is not caused by 
cell lysis buffer . “ A ” denotes Streptococcus bovis ATCC 
700410 ( JB1 ) and “ B ” denotes Fusobacterium necrophorum 
ATCC 27852 in the presence of 50 ul of lysis / extraction 
buffer . Little to no inhibition is seen compared to FIGS . 2 & 
[ 0027 ] Unless defined otherwise , all technical and scien 
tific terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
disclosure belongs . Although any methods and materials 
similar to or equivalent to those described herein can be used 
in the practice or testing of the present disclosure , the 
preferred methods and materials are described below . 
[ 0028 ] In general , the present disclosure is related to the 
use of probiotic bacterial strains Aneurinibacillus migulanus 
and Aneurinibacillus aneurinilyticus , or extracts thereof , for 
inhibiting the growth of Streptococcus bovis , Fusobacterium 
necrophorum and Acranobacterium ( Actinomyces ) pyo 
genes . Accordingly , the methods of the present disclosure 
provide treatment for conditions and ailments resulting from 
overgrowth of Streptococcus bovis , Fusobacterium necro 
phorum and Acranobacterium ( Actinomyces ) pyogenes , for 
example , acidosis , liver abscesses , foot rot , and the like . 
[ 0029 ] " Inhibit ” and / or " reduce ” or other forms of the 
words and their synonyms , such as “ reducing ” or “ reduc 
tion , ” refer to slowing the growth of the so - referenced 
pathogen and / or lowering its incidence . It is understood that 
this is typically in relation to some standard or expected 
value , in other words it is relative , but that it is not always 
necessary for the standard or relative value to be referred to . 
For example , " reduces the population of bacteria ” in certain 
instances refer to lowering the amount of bacteria relative to 
a standard or a control . One preferred control is a similar 
animal or herd of animals that have not received an admin 
istration of the compositions described herein . “ Inhibit ” and 
“ inhibition ” refer to slowing or deterring pathogen growth , 
including pathogenic bacterial growth that would have oth 
erwise occurred except for the provision of the characterized 
deterrent . 
[ 0030 ] By “ treat ” or other forms of the word , such as 
" treated ” or “ treatment , ” means to administer a composition 
or to perform a method in order to reduce , prevent , inhibit , 
break - down , or eliminate a particular characteristic or event 
or reducing , minimizing and / or eliminating diseases , con 
ditions , ailments and / or symptoms thereof caused by bacte 
rial growth , and in particular , growth of Streptococcus bovis , 
Fusobacterium necrophorum and Acranobacterium ( Actino 
myces ) pyogenes . In some embodiments , “ treatment ” , “ treat 
ing " , or " treat ” refer to reversing the progression of condi 
tions or ailments caused by growth of these bacteria . In other 
embodiments , " treatment ” , “ treating " , or " treat ” refer to 
slowing or stopping the progression of conditions or ail 
ments caused by growth of these bacteria . This would 
include slowing or stopping the formation of new abscesses 
or areas of foot rot or slowing or stopping the growth of 
existing abscesses or areas of foot rot . In the context of a 
herd , “ treatment ” , “ treating " , or " treat " can also refer to 
reducing the number of animals that have liver abscesses or 
areas of foot rot . 
[ 0025 ] FIG . 5 depicts growth curves for Streptococcus 
bovis ATCC 700410 ( JB1 ) in the presence of Aneuriniba 
cillus anerinilyticus UNL P2C12 cell extract . The curves 
demonstrate inhibition of growth of Streptococcus bovis 
ATCC 700410 ( JB1 ) in the presence of cell extract . The 
growth curves show that although there is a short lag , the 
lysis / extraction buffer does not inhibit growth . The culture 
growth was measured using optical density ( OD ) at 595 nm . 
Experiment was done in triplicate and mean values are 
plotted . 
10026 ] FIG . 6 depicts in vitro induction of acidosis using 
glucose , showing protection of ruminal pH using the cell 
extract and live cells . The cell extract shows a dose depen 
dent response . Uninduced — No glucose induction , Induced 
Uncontrolled - induced with glucose with no treatment , Cell 
extract 1000 — induced with glucose in the presence of 1000 
US 2019 / 0269740 A1 Sep . 5 , 2019 
[ 0031 ] Aneurinibacillus migulanus ( formerly known as 
Bacillus brevis ) is a producer of the bacteriocins Carnocy 
clin A , Zoocin A , Enterolysin A , Linocin M18 , and uviB . 
[ 0032 ] Similar properties are seen with Aneurinibacillus 
aneurinilyticus ( formerly known as Bacillus aneurinolyti 
cus ) , which produces Zoocin A and uviB . 
[ 0033 ] Both Aneurinibacillus migulanus and Aneuriniba 
cillus aneurinilyticus are probiotic bacterial strains isolated 
from rumen . It has been found that Aneurinibacillus migu 
lanus and Aneurinibacillus aneurinilyticus synthesize and 
excrete extracts that function as antimicrobial compounds ; 
that is , that inhibit the growth of Streptococcus bovis , 
Fusobacterium necrophorum and Acranobacterium ( Actino 
myces ) pyogenes , bacterial strains typically linked to acido 
sis , liver abscesses and foot rot in livestock . 
[ 0034 ] It has been found that by inhibiting Streptococcus 
bovis , Fusobacterium necrophorum and Acranobacterium 
( Actinomyces ) pyogenes , the methods of the present disclo 
sure can treat diseases , conditions and ailments associated 
with infection by Streptococcus bovis , Fusobacterium 
necrophorum and Acranobacterium ( Actinomyces ) pyo 
genes . Exemplary conditions include acidosis and / or its 
direct conditions of liver abscesses and foot rot in livestock . 
[ 0035 ] Other diseases , conditions and ailments can even 
include sore throats such as observed in human subjects . 
[ 0036 ] The methods of the present disclosure , therefore , 
are directed to administering Aneurinibacillus migulanus 
and Aneurinibacillus aneurinilyticus , or extracts thereof , to 
a subject in need thereof . As used herein , “ subject in need 
thereof ” refers to a subset of subjects in need of reducing 
and / or inhibiting growth of Streptococcus bovis , Fusobac 
terium necrophorum and Acranobacterium ( Actinomyces ) 
pyogenes . In one embodiment , subjects that are in specific 
need may include livestock , and in particular cattle , horses , 
pigs , bison , and buffalo , who are susceptible to , or at 
elevated risk of , infection by Streptococcus bovis , Fusobac 
terium necrophorum and Acranobacterium ( Actinomyces ) 
pyogenes . Subjects may be susceptible to , or at elevated risk 
of , infection due to environment , feed , and / or lifestyle . 
While described herein in relation to cattle , it should be 
understood that other livestock may be administered the 
bacterial strains and / or extracts thereof without departing 
from the present disclosure . Further , the bacterial strains or 
extracts thereof can be administered to subjects other than 
livestock to inhibit growth of Streptococcus bovis , Fusobac 
terium necrophorum and Acranobacterium ( Actinomyces ) 
pyogenes . For example , the bacterial strains or extracts 
thereof can be administered to companion animals ( e . g . , 
dogs , cats ) , humans , poultry ( e . g . , chicken , duck , turkey ) . 
Based on the foregoing , because some of the method 
embodiments of the present disclosure are directed to spe 
cific subsets or subclasses of identified subjects ( that is , the 
subset or subclass of subjects “ in need of assistance in 
addressing one or more specific conditions noted herein ) , 
not all subjects will fall within the subset or subclass of 
subjects as described herein for certain conditions and / or 
ailments . 
[ 0037 ] The term “ administering ” as used herein includes 
all means of introducing the bacterial strains and / or their 
extracts described herein to the subject , including , but not 
limited to , including , but not limited to , oral ( po ) , intrave 
nous ( iv ) , intramuscular ( im ) , subcutaneous ( sc ) , parenteral , 
transdermal , inhalation , buccal , ocular , sublingual , vaginal , 
rectal , and the like . The strains and / or extracts described 
herein may be administered in unit dosage forms and / or 
formulations containing conventional nontoxic pharmaceu 
tically - acceptable carriers , adjuvants , and vehicles . 
[ 0038 ] Illustrative formats for oral administration include 
tablets , capsules , elixirs , syrups , and the like . In some 
embodiments , oral administration can be in the form of 
toothpaste such as for the treatment of sore throats in 
subjects . 
[ 0039 ] In particularly suitable embodiments , the methods 
of the present disclosure include incorporating Aneuriniba 
cillus migulanus and / or Aneurinibacillus aneurinilyticus or 
extracts thereof into the diet of the subject as a direct fed 
microbial product . By way of example , the direct fed 
microbial product can be used to supplement livestock feed 
such as cattle feed , horse feed , pig feed , chicken feed , bison 
feed , buffalo feed , duck feed , turkey feed and the like . 
Suitable direct fed microbial products can include live 
cultures or lyophilized preparations . 
10040 ] . In another embodiment , the Aneurinibacillus migu 
lanus and / or Aneurinibacillis aneurinilyticus or extracts 
thereof are administered to the subject as a feed additive 
such as an additive for use in any one or more of the above 
livestock feeds . In one particular embodiment , the Aneurini 
bacillus migulanus and / or Aneurinibacillis aneurinilyticus 
or extracts thereof are administered in amounts ranging from 
about 10 % to about 1011 colony forming units ( CFU ) . In some 
preferred forms , the Aneurinibacillus migulanus and / or 
Aneurinibacillis aneurinilyticus or extracts thereof are 
administered in amounts ranging from about 10° to about 
1010 CFU , with 10° CFU being particularly preferred . 
[ 0041 ] Illustrative routes for parenteral administration 
include intravenous , intraarterial , intraperitoneal , epidural , 
intraurethral , intrasternal , intramuscular and subcutaneous , 
as well as any other art recognized route of parenteral 
administration . 
[ 0042 ] Illustratively , administering includes local use , 
such as when administered locally to the site of inflamma 
tion , infection , injury , or defect , or to a particular organ ( e . g . , 
liver ) or tissue system . Illustrative local administration may 
be performed during open surgery , or other procedures when 
the site of inflammation , infection , injury , or defect is 
accessible . Alternatively , local administration may be per 
formed using parenteral delivery where the bacterial strains / 
extracts described herein is deposited locally to the site 
without general distribution to multiple other non - target 
sites in the subject being treated . It is further appreciated that 
local administration may be directly in the injury site , or 
locally in the surrounding tissue . Similar variations regard 
ing local delivery to particular tissue types , such as organs , 
and the like , are also described herein . 
[ 0043 ] Suitable lubricants include , for example , water 
based lubricants , oil - based lubricants , and silicone - based 
lubricants . Particularly suitable lubricants include , for 
example , glycerin , hydroxyethyl cellulose , xylitol , carra 
geenan , and combinations thereof . 
[ 0044 ] In yet other embodiments , administration includes 
topical administration by use of a topical composition , such 
as a spray composition , a lotion , an ointment , an aqueous 
composition , or the like . When used as a topical composi 
tion , the composition can include other components typi 
cally included in topical sprays , lotions , and / or ointments in 
combination with the Aneurinibacillus migulanus and / or 
Aneurinibacillis aneurinilyticus or extracts thereof as known 
in the topical arts without departing from the present dis 
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closure . In one particularly suitable embodiment , the Aneu 
rinibacillus migulanus and / or Aneurinibacillis aneurinilyti - 
cus or extracts thereof are incorporated into a composition in 
the form of a foot bath such that a subject can contact the 
foot bath by walking through the bath to apply the compo 
sition . 
[ 0045 ] In some embodiments , a therapeutically effective 
amount of Aneurinibacillus migulanus and / or Aneuriniba 
cillis aneurinilyticus or extracts thereof in any of the various 
forms described herein may be mixed with one or more 
excipients , diluted by one or more excipients , or enclosed 
within such a carrier which can be in the form of a capsule , 
sachet , paper , or other container . Excipients may serve as a 
diluent , and can be solid , semi -solid , or liquid materials , 
which act as a vehicle , carrier or medium for the active 
ingredient . Thus , the Aneurinibacillus migulanus and / or 
Aneurinibacillis aneurinilyticus or extracts thereof can be 
administered in the form of tablets , pills , powders , lozenges , 
sachets , cachets , elixirs , suspensions , emulsions , solutions , 
syrups , aerosols ( as a solid or in a liquid medium ) , oint 
ments , soft and hard gelatin capsules , suppositories , sterile 
injectable solutions , and sterile packaged powders . 
10046 ] The term “ therapeutically effective amount ” as 
used herein , refers to that amount of active compound or 
agent that elicits the biological or medicinal response in a 
tissue system , animal or human that is being sought by a 
researcher , veterinarian , medical doctor or other clinician , 
which includes alleviation of the symptoms of the disease , 
condition or ailment being treated . In one aspect , the thera 
peutically effective amount is that which may treat or 
alleviate the condition , disease or symptoms of the disease 
at a reasonable benefit / risk ratio applicable to any medical 
treatment . However , it is to be understood that the total 
weekly usage of the Aneurinibacillus migulanus and / or 
Aneurinibacillis aneurinilyticus or extracts thereof 
described herein may be decided by the attending physician 
or veterinarian within the scope of sound medical judgment . 
The specific therapeutically - effective dose level for any 
particular patient will depend upon a variety of factors , 
including the severity of the condition being treated ; the 
specific composition employed ; the age , body weight , gen 
eral health , gender and diet of the patient : the time of 
administration , route of administration , and the duration of 
the treatment ; drugs used in combination or coincidentally 
with the Aneurinibacillus migulanus and / or Aneurinibacillis 
aneurinilyticus or extracts thereof ; and like factors well 
known to the researcher , veterinarian , medical doctor or 
other clinician of ordinary skill . 
[ 0047 ] It is also appreciated that the therapeutically effec 
tive amount is advantageously selected with reference to any 
toxicity , or other undesirable side effect , that might occur 
during administration of the Aneurinibacillus migulanus 
and / or Aneurinibacillis aneurinilyticus or extracts thereof . 
[ 0048 ] In particular embodiments , such as when the Aneu 
rinibacillus migulanus and / or Aneurinibacillis aneurinilyti 
cus or extracts thereof are administered as a feed additive , 
the Aneurinibacillus migulanus and / or Aneurinibacillis 
aneurinilyticus or extracts thereof are administered in 
amounts to provide from about 100 to about 1011 CFU , more 
preferably 108 to 1010 CFU , and most preferably about 109 
CFU per head per day . 
[ 0049 ] In some embodiments , the Aneurinibacillus migu 
lanus and / or Aneurinibacillis aneurinilyticus or extracts 
thereof are administered with at least one prebiotic . Prebi 
otics exert health benefits , which may include , but are not 
limited to , selective stimulation of the growth and / or activity 
of one or a limited number of beneficial gut bacteria , 
stimulation of the growth and / or activity of ingested probi 
otic microorganisms , selective reduction in gut pathogens , 
and favorable influence on gut short chain fatty acid profile . 
Some combinations of Aneurinibacillus migulanus and / or 
Aneurinibacillis aneurinilyticus or extracts thereof and / or at 
least one prebiotic will act synergistically with one another . 
Such prebiotics may be naturally - occurring , synthetic , or 
developed through the genetic manipulation of organisms 
and / or plants , whether such new source is now known or 
developed later . Prebiotics useful in the present disclosure 
may include soluble starch , yeast extract , oligosaccharides , 
polysaccharides , and other prebiotics that contain fructose , 
xylose , soya , galactose , glucose and mannose . Of these , 
soluble starch and yeast extract are particularly preferred for 
some forms . Corn has a high amount of soluble starch and 
distillers grains which comes as a by - product of ethanol 
fermentation has yeast and yeast extract as by products . Both 
corn and distillers grains are widely used in cattle diets and 
as such Aneurinibacillus migulanus and / or Aneurinibacillis 
aneurinilyticus will grow well when mixed with corn or 
distillers grains and fed . 
[ 0050 ] More specifically , prebiotics useful in the present 
disclosure may include soluble starch , yeast extract , poly 
dextrose , polydextrose powder , lactulose , lactosucrose , 
raffinose , gluco - oligosaccharide , inulin , fructo - oligosaccha 
ride , isomalto - oligosaccharide , soybean oligosaccharides , 
lactosucrose , xylo - oligosaccharide , chito - oligosaccharide , 
manno - oligosaccharide , aribino - oligosaccharide , siallyl - oli 
gosaccharide , fuco - oligosaccharide , galacto - oligosaccha 
ride , and gentio - oligosaccharides . 
[ 0051 ] In an embodiment , the total amount of prebiotics 
present in the composition may be from about 1 . 0 g / L to 
about 10 . 0 g / L of the composition . More preferably , the total 
amount of prebiotics present in the nutritional composition 
may be from about 2 . 0 g / L and about 8 . 0 g / L of the 
composition . In some embodiments , the total amount of 
prebiotics present in the nutritional composition may be 
from about 0 . 1 g / 100 kcal to about 1 g / 100 kcal . In certain 
embodiments , the total amount of prebiotics present in the 
nutritional composition may be from about 0 . 3 g / 100 kcal to 
about 0 . 7 g / 100 kcal . 
[ 0052 ] The prebiotics of this disclosure can be in the same 
capsule or formulation as the probiotics , or in a separate 
dosage form . The prebiotics of this disclosure may also be 
taken with carbohydrate or fiber to increase their effective 
ness . 
[ 0053 ] The compositions of the present disclosure can also 
include one or more additional active ingredients , excipi 
ents , dissolution agents , surfactants , antioxidants , antisep 
tics , preservatives , penetrants , and combinations thereof . 
[ 0054 ] Various excipients can be mixed with the compo 
sitions as would be known to those skilled in the art . Suitable 
excipients include , for example , microcrystalline cellulose , 
colloidal silicon dioxide , lactose , starch , sorbitol , cyclodex 
trin and combinations thereof . 
[ 0055 ] Suitable dissolution agents include , for example , 
organic acids such as citric acid , fumaric acid , tartaric acid , 
succinic acid , ascorbic acid , acetic acid , malic acid , glutaric 
acid and adipic acid , and can be used alone or in combina 
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EXAMPLES 
Example 1 
[ 0064 ] In this Example , the inhibitory abilities of bacterial 
strains against Streptococcus bovis and Fusobacterium 
necrophorum were analyzed . 
Methods 
tion . These agents can also be combined with salts of the 
acids , e . g . sodium citrate with citric acid , to produce a buffer 
system . 
[ 0056 ] Suitable surfactants include , for example , sodium 
lauryl sulphate , polyethylene separates , polyethylene sorbi 
tan fatty acid esters , polyoxyethylene castor oil derivatives , 
polyoxyethylene alkyl ethers , benzyl benzoate , cetrimide , 
cetyl alcohol , docusate sodium , glyceryl monooleate , glyc 
eryl monostearate , glyceryl palmitostearate , lecithin , 
medium chain triglycerides , monoethanolamine , oleic acid , 
poloxamers , polyvinyl alcohol and sorbitan fatty acid esters . 
[ 0057 ] Suitable antioxidants include , for example , sodium 
metabisulfite ; tocopherols such as a , ß , d - tocopherol esters 
and a - tocopherol acetate ; ascorbic acid and pharmaceuti 
cally acceptable salts thereof ; ascorbyl palmitate ; alkyl 
gallates ( e . g . , propyl gallate , TENOX® PG , TENOX® S - 1 ) ; 
sulfites and pharmaceutically acceptable salts thereof buty 
lated hydroxyanisole ; butylated hydroxytoluene ; and mono 
thioglycerol . 
[ 0058 ) Suitable antiseptics include , for example , chlo 
rhexidine gluconate , glucono delta - lactone , methylparaben , 
sodium hydroxide , and combinations thereof . 
[ 0059 ] Suitable preservatives include parabens . Suitable 
parabens include , for example , methylparaben ( E number 
E218 ) , ethylparaben ( E214 ) , propylparaben ( E216 ) , butyl 
paraben and heptylparaben ( E209 ) . Less common parabens 
include isobutylparaben , isopropylparaben , benzylparaben 
and their sodium salts . 
[ 0060 ] Suitable penetrants include , for example , sulphox 
ides ( e . g . , dimethyl sulphoxide , dimethylacetamide , dimeth 
ylformamide ) , azone ( 1 - dodecylazacycloheptan - 2 - one or 
laurocapran ) , pyrrolidones ( e . g . , N - methyl - 2 - pyrolidone ) , 
fatty acids ( e . g . , oleic acid , lauric acid , myristic acid , capric 
acid ) , essential oils ( e . g . , eucalyptus , chenopodium , ylang 
ylang , L - menthol ) , terpenes ( e . g . , sesquiterpene ) , terpe 
noids , oxazolidinones ( e . g . , 4 - decyloxazolidin - 2 - one ) , and 
urea . 
[ 0061 ] In some forms , Aneurinibacillus migulanus and / or 
Aneurinibacillis aneurinilyticus or extracts thereof are 
administered separately . In other forms , they are adminis 
tered together . Preferably the combination of Aneuriniba 
cillus migulanus and / or Aneurinibacillis aneurinilyticus or 
extracts thereof will act synergistically . 
[ 0062 ] When producing a lyophilized form of Aneurini 
bacillus migulanus and / or Aneurinibacillis aneurinilyticus , 
overnight cultures were centrifuged at 3000xg for 15 min at 
room temperature and the resulting cell pellet was sus 
pended in 10 ml of 20 % glycerol in spent media resuspen 
sion solution ( the media collected after centrifugation was 
mixed with 50 % sterile glycerol to generate a 20 % resus 
pension solution ) . The resulting cell suspension was snap 
frozen in liquid nitrogen and was then freeze dried to obtain 
a freeze dried viable cell product . 10 milligrams of the freeze 
dried cells were suspended in peptone water and was spread 
on brain heart infusion agar plates to determine viable 
colony forming units ( CFUS ) per milligram of freeze dried 
product . 
[ 0063 ] The following examples further illustrate specific 
embodiments of the present disclosure ; however , the fol 
lowing illustrative examples should not be interpreted in any 
way to limit the disclosure . 
[ 0065 ] Isolation of the Bacterial Strains 
[ 0066 ] Rumen samples were collected through a rumen 
fistula from 4 animals . Each animal was on a different diet 
( animal # 6396 — deoiled modified distillers plus solubles 
with added corn oil ; animal # 6393 — Full fat modified dis 
tillers plus solubles ; animal # 6398 _ dry rolled corn and high 
moisture corn ; and animal # 6394 — deoiled modified distill 
ers grains plus solubles ) . Equal amounts ( ~ 10 grams ) of each 
rumen sample were mixed together in a 50 ml conical tube 
and sterile PBS was added to the top of the tube and shaken 
vigorously for 5 minutes using a vortexer . Aliquotes of the 
sample was incubated at 70° C . for 1 hour to reduce the 
growth of vegetative cells . The sample was serially diluted 
( 101 - 104 ) and plated on ISP 2 , ISP 4 and casein starch agar 
( Himedia Laboratories , India ) with 50 ug / ml cycloheximide 
( Sigma Aldrich , St Louis , Mo . ) and 20 ug / ml Nalidixic acid 
( Acros Organics , NJ ) . The plates were incubated anaerobi 
cally at 37° C . for 14 days . 
[ 0067 ] Screening for Isolates Against Streptococcus bovis 
and Fusobacterium necrophorum 
[ 0068 ] On day 14 , colonies were picked into 96 - well 
plates containing tryptic soy broth ( TSB ) ( BD BactoTM , 
Sparks MD ) and were incubated anaerobically and aerobi 
cally at 37° C . Screening for isolates that are inhibitory 
towards Streptococcus bovis and Fusobacterium necropho 
rum was performed as follows . Briefly , 100 ul of overnight 
cultures of Streptococcus bovis ( ATCC 700410 ( JB1 ) ) and 
2 - day cultures of Fusobacterium necrophorum 
( ATCC27852 ) , were plated on Brain Heart Infusion ( BD 
BBLTM , Sparks , MD ) plates and were spotted with isolates . 
The Streptococcus bovis test organism was grown on TSB 
and Fusobacterium necrophorum was grown on cooked 
meat medium ( Hardy Diagnostics ) . The plating was done in 
duplicate and was incubated both aerobically and anaerobi 
cally at 37° C . Plates were checked periodically for clear 
zones around the isolates , which was indicative of the isolate 
producing an inhibitory product against the test strain . 
Positive isolates were regrown from the 96 - well plates and 
glycerol stocks were prepared for archiving , which con 
tained 20 % glycerol . Two isolates with the capacity to 
inhibit the growth of Streptococcus bovis and Fusobacte 
rium necrophorum were identified for further investigation 
( see FIG . 1 ) . 
[ 0069 ] Characterization of the Microbial Strains 
100701 To characterize the microbial isolates and to con 
firm the identity of the test strains , 16S rRNA gene was 
sequenced . Briefly , overnight cultures of each strain were 
used for DNA extraction using the QUICKEXTRACTTM 
Bacteria DNA extraction kit ( Epicenter , Madison , Wis . ) 
according to the manufacturer ' s protocol . The resulting 
DNA was used for PCR using universal 16S rRNA primers 
( 27F and 1492R ) ( Baker et al . , Review and re - analysis of 
domain - specific 16S primers , J . Microbiol . Methods 2003 , 
55 ( 3 ) : 541 - 555 ) . The PCR was done using the TerraTM PCR 
Direct polymerase mix according to the manufacturer ' s 
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[ 0075 ] Growth curves of Streptococcus bovis in the pres 
ence of the cell lysate of Aneurinibacillus anerinilyticus 
UNL P2C12 
[ 0076 ] Growth curves for Streptococcus bovis were per 
formed using cell extracts of Aneurinibacillus anerinilyticus 
UNLP2C12 . Briefly , an overnight culture of Streptococcus 
bovis was diluted in sterile media to bring the OD595 to 0 . 2 
units . One hundred microliters of the diluted culture was 
dispensed into wells of a 96 - well sterile culture plate and the 
following treatments were imposed each in triplicate . 
Samples included : Blank ( only sterile media ) , Cells ( 0 . 2 OD 
culture cells ) , Cells + 30 ul of the lysate , Cells + 50 ul of the 
lysate , Cells + lysis buffer . Volumes of all the wells were 
bought up to 150 ul using sterile media except for the 
treatment with Cells + 50 ul of the lysate as the volume was 
already 150 ul in this treatment . The plate was incubated 
anaerobically using an anaerobic jar at 37° C . The cell 
growth was measured using optical density ( OD at 595 nm ) 
at 0 , 4 , 22 . 75 , and 27 hours of incubation . See Table 1 and 
FIG . 5 . Growth curves for Fusobacterium necrophorum was 
not performed as this organism is a strict anaerobe and 
therefore hard to go in and out of the anaerobic jar to 
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protocol ( Clonetech Laboratories , Mountain view , CA ) . The 
PCR conditions were , 98° C . for 2 minutes , followed by 35 
cycles of 98° C . for 10 seconds , 60° C . for 30 seconds , and 
68° C . for 90 seconds . A final extension of 68° C . for 4 
minutes was used at the end of the 35 cycles . The PCR 
products were visualized using agarose gel electrophoresis 
to ensure a single product . The resulting product was puri 
fied using shrimp alkaline phosphatase and exonuclease as 
described in Sambrook et al . , Molecular Cloning : A Labo 
ratory Manual , 2 edn . New York : Cold Spring Harbor 
Laboratory Press ; 1989 , and was sequenced from both 
directions using the 27F and 1492 primers . Sequencing was 
performed at Eurifins Genomics according to their proto 
cols . The sequencing results generated were matched against 
the NCBI non - redundant database and the ribosomal data 
base project ( Cole et al . , The Ribosomal Database Project 
( RDP - II ) : sequences and tools for high - throughput rRNA 
analysis . Nucleic Acids Res 2005 , 33 : D294 - 296 ; Maidak et 
al . , The RDP - II ( Ribosomal Database Project ) . Nucleic 
Acids Res 2001 , 29 ( 1 ) : 173 - 174 ) to identify the taxonomic 
classification of the unknown isolates and also to verify the 
taxonomy of the test strains ( SEQ ID NO : 1 and SEQ ID 
NO : 2 ) . 
[ 0071 ] Preparing Cell Extracts for Antimicrobial Assays 
[ 0072 ] Based on the 16S sequencing results , both isolates 
were identified to belong to the genus Aneurinibacillus ( A . 
migulanus ( SEQ ID NO : 2 ) and A . anerinilyticus ( SEQ ID 
NO : 1 ) ) . Based on published studies ( Berditsch M , Afonin S , 
Ulrich A S : The ability of Aneurinibacillus migulanus ( Ba 
cillus brevis ) to produce the antibiotic gramicidin S is 
correlated with phenotype variation . Appl Environ Microbiol 
2007 , 73 ( 20 ) : 6620 - 6628 ) , the cell extracts of the two iso 
lates were purified . Briefly , 5 ml of the cultures were 
centrifuged at 3000xg for 15 minutes at room temperature . 
The supernatant was collected and lyophilized to evaluate 
secreted inhibitory product . Additionally , the cell pellet was 
resuspended in the lysis buffer ( 150 mM NaCl and 20 mM 
HCI ) and was incubated at 80° C . for 15 minutes , followed 
by addition of absolute ethanol ( 1 : 1 mix - final concentra 
tion of 50 % ) . The slurry was then incubated at room 
temperature with gentle horizontal agitation for 1 hour . 
Following , extraction with ethanol , the slurry was centri 
fuged and the supernatant was collected , which contained 
the ethanoilic cell extract . 
[ 0073 ] Antimicrobial Assays Against Streptococcus bovis 
and Fusobacterium necrophorum 
[ 0074 ] Both the ethanolic cell extract and the lyophilized 
cell free media were used for agar disk diffusion antimicro 
bial assays . The Kirby - Bauer Disk Diffusion Susceptibility 
test was performed as described in Hudzcki : Kirby - Bauer 
Disk Diffusion Susceptibility Test Protocol : American Soci 
ety of microbiology ; 2009 , with the exception of using 
Mueller Hinton agar plates with 5 % sheep blood ( purchased 
from BD BBLTM , Sparks , MD ) instead of regular Mueller 
Hinton agar plates without blood . This was done because of 
the fastidious nature of Fusobacterium necrophorum . In 
addition to the assays , a control assay was performed to 
demonstrate that the inhibition of the test strains were a 
result of the inhibitory compound and not a result of the 
extraction / lysis buffer used . See FIGS . 2 - 4 for results of the 
antimicrobial assays . The blood agar plate assays also dem 
onstrated that the Aneurinibacillus migulanus strain is 
hemolytic . All incubations were performed in an anaerobic 
jar at 37° C . 
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[ 0077 ] In Vitro Analysis of pH Control During Acidosis 
Induction 
10078 ] The in vitro analysis was performed . Briefly , Aneu 
rinibacillus anerinilyticus UNL P2C12 was grown overnight 
and used to inoculate 1 L culture media to grow enough cells 
for and to extract adequate amounts of cell lysate for the in 
vitro experiments . The cultures were grown overnight aero 
bically at 37°C . This was done because the Aneurinibacillus 
anerinilyticus UNL P2C12 isolate is facultative and can be 
grown both aerobically and anaerobically , but grows faster 
aerobically . Part of the overnight growth was flash frozen in 
liquid nitrogen in the presence of 20 % glycerol to use as live 
culture inoculants in the in vitro experiments . The rest of the 
culture was used to extract the cell lysate as described above . 
Glucose was used to induce acidosis as described by Hutton 
et al . ( In Vitro Screening of Plant Resources for Extra 
nutritional Attributes in Ruminants : Nuclear and Related 
Methodologies Springer ; 2009 : 159 - 189 ) . The following 
treatments were used . 
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was poured to a large beaker and was stirred . Ten milliliters 
of the rumen fluid was added to each tube inside the 
anaerobic chamber . All tubes except for the uninduced 
treatment received 1 gram of glucose and was used to induce 
acidosis . The treatments were imposed as shown above . The 
tubes were sealed using butyl rubber stoppers and were 
crimped with aluminum caps . The gas was equilibrated 
before bringing the tubes out of the anaerobic chamber using 
a 23 - gauge needle . The sealed tubes were brought out of the 
anaerobic chamber and were vortexed to mix the contents 
and glucose and were incubated at 39° C . with gentle 
agitation ( 50 rpm ) . 
[ 0080 ] Tubes were removed at 0 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 hours . 
Each tube was opened and the pH was recorded . Results of 
the in vitro assay are shown in FIG . 6 . 
[ 0079 ] Briefly , rumen samples were collected anaerobi 
cally into a warm thermos as described by Hutton et al . The 
rumen samples were collected from a fistulated steer 2 hours 
after feeding . The rumen fluid collected was transported to 
the laboratory and was opened inside the anaerobic chamber . 
This process from sampling to opening in the chamber took 
between 15 - 20 minutes . Inside the chamber , the rumen fluid 
SEQUENCE LISTING 
< 160 > NUMBER OF SEQ ID NOS : 2 
V 
< 210 > SEQ ID NO 1 
1 > LENGTH : 804 
212 > TYPE : DNA 
< 213 > ORGANISM : Aneurinibacillus aneurinolyticus 
V 
< 400 > SEQUENCE : 1 
cttgctcttc ggcggttagc ggcggacggg tgagtaacac gtaggcaacc tgcctgtacg 60 
actgggataa ctccgggaaa ccggagctaa taccggatac gtttttcaga ccgcatggto 120 
tgaaagagaa agacctttgg tcacgtacag atgggcctgc ggcgcattag ctagttggtg 180 
gggtaacggc ctaccaaggc gacgatgcgt agccgacctg agagggtgat cggccacact 240 
gggactgaga cacggcccag actcctacgg gaggcagcag tagggaatct tccgcaatgg 300 
acgaaagtct gacggagcaa cgccgcgtga acgatgaagg ttttcggatc gtaaagttct 360 
gttgttaggg aagaaccgcc gggatgacct cccggtctga cggtacctaa cgagaaagcc 420 
ccggctaact acgtgccagc agccgcggta atacgtaggg ggcaagcgtt gtccggaatt 480 
attgggcgta aagcgcgcgc aggcggcttc ttaagtcagg tgtgaaagcc cacggctcaa 540 
ccgtggaggg ccacttgaaa ctgggaggct tgagtgcagg agaggagagc ggaattccac 600 
gtgtagcggt gaaatgcgta gagatgtgga ggaacacocg tggcgaaggc ggctctctgg 660 
cctgtaactg acgctgaggc gcgaaagcgt ggggagcgaa caggattaga taccctggta 720 
gtccacgccg taaacgttga gtgctaggtg ttggggactc caatcctcag tgccccagct 780 
aacgcaataa gcactccgcc tggg 804 
< 210 > SEQ ID NO 2 
< 211 > LENGTH : 755 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Aneurinibacillus migulanus NNNN 
< 400 > SEQUENCE : 2 
cagagcttgc tcttcggcgg ttagcggcgg acgggtgagt aacacgtagg caacctgcct 60 
gtacgactgg gataactccg ggaaaccgga getaataccg gatacttctt tcagaccgca 120 
tggtctgaaa gggaaagacc tttggtcacg tacagatggg cctgcggcgc attagctagt 180 
tggtggggta acggcctacc aaggcgacga tgcgtagccg acctgagagg gtgatcggcc 240 
acactgggac tgagacacgg cccagactcc tacgggaggc agcagtaggg aatcttccgc 300 
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aatggacgaa agtctgacgg agcaacgccg cgtgaacgat gaaggttttc ggatcgtaaa 360 
gttctgttgt tagggaagaa ccgccgggat gacctcccgg tctgacggta cctaacgaga 420 
aagccccggc taactacgtg ccagcagccg cggtaatacg tagggggcaa gcgttgtccg 480 
gaattattgg gcgtaaagcg cgcgcaggcg gottcttaag tcaggtgtga aagcccacgg 540 
ctcaaccgtg gagggccact tgaaactggg aagcttgagt gcaggagagg agagoggaat 600 
tccacgtgta gcggtgaaat gcgtagagat gtggaggaac acccgtggcg aaggcggctc 660 
tctggcctgt aactgacgct gaggcgcgaa agcgtgggga gcgaacagga ttagataccc 720 
tggtagtcca cgccgtaaac gttgagtgct aggtg 755 
1 . A composition comprising : 
a . from about 108 to about 1011 colony forming units 
( CFU ) of a bacterial strain or extract thereof selected 
from the group selected from the group consisting of 
Aneurinibacillus migulanus , Aneurinibacillus aneu 
rinilyticus , and any combination thereof ; and 
b . a prebiotic selected from the group consisting of 
soluble starch , yeast extract , oligosaccharides , polysac 
charides , and other prebiotics that contain fructose , 
xylose , soya , galactose , glucose , mannose , and any 
combination thereof in an amount from about 1 . 0 g / L 
to about 10 . 0 g / L of the composition . 
2 . ( canceled ) 
3 . The composition of claim 1 , wherein the composition 
includes both Aneurinibacillus migulanus or an extract 
thereof , Aneurinibacillus aneurinilyticus or an extract 
thereof . 
4 - 5 . ( canceled ) 
6 . The composition of claim 1 , wherein the bacterial strain 
or extract thereof is in a lyophilized form . 
7 . The composition of claim 6 , wherein the lyophilized 
form further comprises glycerol . 
8 . The composition of claim 1 , wherein the extract of the 
biological composition comprises at least one bacteroicin 
selected from the group consisting of Carnocyclin A , Zoocin 
A , Enterolysin A , Linocin M18 , uviB , and any combination 
thereof . 
9 . The composition of claim 1 , further comprising a 
component selected from the group consisting of one or 
more excipients , carriers , active ingredients , dissolution 
agents , surfactants , antioxidants , antiseptics , preservatives , 
penetrants , and any combination thereof . 
10 . A method of inhibiting a bacteria selected from the 
group consisting of Streptococcus bovis , Fusobacterium 
necrophorum , Acranobacterium ( Actinomyces ) pyogenes 
and any combination thereof in a subject in need thereof , the 
method comprising administering to the subject an effective 
amount of a bacterial strain selected from the group con 
sisting of Aneurinibacillus migulanus or an extract thereof , 
Aneurinibacillus aneurinilyticus or an extract thereof and 
any combination thereof . 
11 . The method as set forth in claim 10 , wherein the 
bacterial strain or extract thereof is administered in a form 
selected from the group consisting of a direct fed microbial 
product , a feed additive , a toothpaste , a topical composition , 
or any combination thereof . 
12 . The method as set forth in claim 11 , wherein the direct 
fed microbial product can be used to supplement at least one 
livestock feed selected from the group consisting of cattle 
feed , pig feed , chicken feed , bison feed , buffalo feed , duck 
feed and turkey feed . 
13 - 14 . ( canceled ) 
15 . The method as set forth in claim 11 , wherein the 
topical composition is in a form selected from the group 
consisting of a spray composition , a lotion , an ointment , a 
footbath , or any combination thereof . 
16 - 17 . ( canceled ) 
18 . The method as set forth in claim 10 , wherein the 
subject is selected from the group consisting of livestock , 
companion animal , and poultry . 
19 . The method as set forth in claim 10 , further compris 
ing the step of administering an effective amount of a 
prebiotic . 
20 . The method as set forth in claim 10 , wherein the 
effective amount of the bacterial strain comprises from about 
108 to about 1011 colony forming units ( CFU ) . 
21 - 43 . ( canceled ) 
44 . A method of reducing the incidence or severity of a 
condition selected from the group consisting of acidosis , 
liver abscesses , foot rot , or any combination thereof in a 
subject in need thereof , the method comprising administer 
ing to the subject an effective amount of a bacterial strain 
selected from the group consisting of Aneurinibacillus migu 
lanus or an extract thereof , Aneurinibacillus aneurinilyticus 
or an extract thereof , and any combination thereof . 
45 . The method as set forth in claim 44 , wherein the 
bacterial strain or extract thereof is administered in a form 
selected from the group consisting of a direct fed microbial 
product , a feed additive , a topical composition , a toothpaste , 
or any combination thereof . 
46 . The method as set forth in claim 45 , wherein the direct 
fed microbial product can be used to supplement at least one 
livestock feed selected from the group consisting of cattle 
feed , pig feed , chicken feed , bison feed , buffalo feed , duck 
feed and turkey feed . 
47 . ( canceled ) 
48 . The method as set forth in claim 44 , wherein the 
effective amount of the bacterial strain administered is from 
about 10° to about 10 " cells per head per day . 
49 . The method as set forth in claim 44 , wherein the 
subject is selected from the group consisting of livestock , 
companion animal , and poultry . 
50 . The method as set forth in claim 44 , further compris 
ing the step of administering an effective amount of a 
prebiotic . 
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51 . The method as set forth in claim 44 , wherein the 
effective amount of the bacterial strain comprises from about 
108 to about 1011 colony forming units ( CFU ) . 
52 - 68 . ( canceled ) 
